Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts assign Alto Neuroscience a “Moderate Buy” consensus: Eight of 11 analysts recommend buying the stock, while two rate it a sell and one recommends holding. The average 12-month price target is $35.25, above the reported $27.09 opening price.
• Recent analyst actions were mixed, including price-target increases from Wedbush, a target cut from Robert W. Baird, and a downgrade from Zacks Research to “strong sell.”
• Institutional investor interest increased significantly during the fourth quarter and first quarter, with several firms establishing or expanding sizable positions. However, Alto missed its latest quarterly earnings estimate, reporting an adjusted loss of $0.80 per share versus the expected $0.56 loss.

Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven analysts that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $35.25.

Several analysts recently weighed in on ANRO shares. Chardan Capital reiterated a "buy" rating and issued a $30.00 price target on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Robert W. Baird reduced their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an "outperform" rating on the stock in a research report on Monday, May 18th. HC Wainwright reissued a "buy" rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Zacks Research lowered shares of Alto Neuroscience from a "hold" rating to a "strong sell" rating in a report on Wednesday, July 22nd. Finally, Wedbush lifted their price objective on Alto Neuroscience from $21.00 to $24.00 and gave the company a "neutral" rating in a research report on Thursday, May 14th.

Alto Neuroscience Trading Up 0.1%

ANRO opened at $27.09 on Monday. The business has a 50 day simple moving average of $24.11 and a two-hundred day simple moving average of $21.94. The firm has a market capitalization of $950.87 million, a price-to-earnings ratio of -11.20 and a beta of 1.04. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. Alto Neuroscience has a one year low of $3.00 and a one year high of $28.85.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.24). Analysts predict that Alto Neuroscience will post -3.14 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ANRO. Commodore Capital LP purchased a new stake in shares of Alto Neuroscience in the 4th quarter worth about $32,453,000. Perceptive Advisors LLC increased its stake in shares of Alto Neuroscience by 1,048.5% in the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company's stock worth $31,762,000 after acquiring an additional 1,629,027 shares in the last quarter. Vestal Point Capital LP lifted its position in Alto Neuroscience by 161.6% during the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company's stock valued at $44,233,000 after acquiring an additional 1,535,000 shares during the period. Spruce Street Capital LP lifted its position in Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company's stock valued at $29,116,000 after acquiring an additional 1,102,366 shares during the period. Finally, Vivo Capital LLC bought a new stake in Alto Neuroscience during the fourth quarter worth about $18,433,000.

About Alto Neuroscience

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source